Welcome to our dedicated page for GW Pharma news (Ticker: GWPH), a resource for investors and traders seeking the latest updates and insights on GW Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GW Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GW Pharma's position in the market.
GW Pharmaceuticals announced a virtual investor event on June 30, 2020, to discuss the U.S. development program for its late-stage drug, nabiximols. The event will run from 10:00 am to 12:00 pm EDT and will feature experts and executives, with a replay available on their website afterward. Nabiximols is set to enter Phase 3 trials focused on treating MS spasticity, with further indications planned for spinal cord injury spasticity and PTSD. Nabiximols, known as Sativex outside the U.S., has shown positive results in Europe for MS spasticity.
GW Pharmaceuticals reported total revenue of $120.6 million for Q1 2020, a significant increase from $39.2 million in Q1 2019. Net product sales of Epidiolex were $116.1 million, with U.S. sales at $106.1 million. The company is poised for growth, especially with a planned launch for a Tuberous Sclerosis Complex (TSC) indication in August, following FDA priority review. Despite a net loss of $8.0 million this quarter, down from $50.1 million last year, GW maintains a strong balance sheet with $500.9 million in cash and equivalents.
Summary not available.